ES2142729B1 - PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES. - Google Patents

PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.

Info

Publication number
ES2142729B1
ES2142729B1 ES009701666A ES9701666A ES2142729B1 ES 2142729 B1 ES2142729 B1 ES 2142729B1 ES 009701666 A ES009701666 A ES 009701666A ES 9701666 A ES9701666 A ES 9701666A ES 2142729 B1 ES2142729 B1 ES 2142729B1
Authority
ES
Spain
Prior art keywords
strains
protein product
preparation
group
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009701666A
Other languages
Spanish (es)
Other versions
ES2142729A1 (en
Inventor
Mejias Fernando Chacon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES009701666A priority Critical patent/ES2142729B1/en
Priority to AU84424/98A priority patent/AU8442498A/en
Priority to PCT/ES1998/000219 priority patent/WO1999006441A1/en
Publication of ES2142729A1 publication Critical patent/ES2142729A1/en
Application granted granted Critical
Publication of ES2142729B1 publication Critical patent/ES2142729B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Producto proteico, procedimiento para su preparación, composiciones, que lo contienen, y su uso en medicamentos. Se describe un producto proteico extraído de bacilos apatógenos que comprende proteínas, péptidos y otras moléculas, obtenidos a patir de lisis celular de al menos una de las de cepas de bacilos, termorresistentes y esporulados, naturales o modificadas, y seleccionadas: un primer grupo compuesto por cepas de B. Licheniformis, B.Circulans 2, B. Pumilus, B. Macerans, B. Amilolicuofaciens;un segundo grupo compuesto por cepas de B. Cereus 1, B. Cereus 2, B. Lentus 1, B. Lentus 2; un tercer grupo compuesto por cepas de B. Subtilis; un cuarto grupo compuesto por cepas de B. Mesentericus. También se describe un procedimiento de preparación del producto proteico, composiciones que lo contienen y su uso en la preparación de medicamentos para el tratamiento de enfermedades relacionadas con síndromes de inmunodeficiencia, autoinmunidad, procesos neoplásicos, enfermedades articulares degenerativas y enfermedades inflamatorias intestinales.Protein product, procedure for its preparation, compositions that contain it, and its use in medicines. A protein product extracted from apathogenic bacilli is described, comprising proteins, peptides and other molecules, obtained by cell lysis from at least one of the strains of bacilli, heat-resistant and sporulated, natural or modified, and selected: a first compound group by strains of B. Licheniformis, B. Circulans 2, B. Pumilus, B. Macerans, B. Amilolicuofaciens; a second group consisting of strains of B. Cereus 1, B. Cereus 2, B. Lentus 1, B. Lentus 2 ; a third group consisting of B. subtilis strains; a fourth group consisting of B. Mesentericus strains. Also described is a process for preparing the protein product, compositions containing it, and its use in the preparation of drugs for the treatment of diseases related to immunodeficiency syndromes, autoimmunity, neoplastic processes, degenerative joint diseases and inflammatory bowel diseases.

ES009701666A 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES. Expired - Fee Related ES2142729B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES009701666A ES2142729B1 (en) 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.
AU84424/98A AU8442498A (en) 1997-07-29 1998-07-28 Proteinic product, process for its preparation, compositions containing it and use in medicaments
PCT/ES1998/000219 WO1999006441A1 (en) 1997-07-29 1998-07-28 Proteinic product, process for its preparation, compositions containing it and use in medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701666A ES2142729B1 (en) 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.

Publications (2)

Publication Number Publication Date
ES2142729A1 ES2142729A1 (en) 2000-04-16
ES2142729B1 true ES2142729B1 (en) 2000-12-16

Family

ID=8300210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009701666A Expired - Fee Related ES2142729B1 (en) 1997-07-29 1997-07-29 PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.

Country Status (3)

Country Link
AU (1) AU8442498A (en)
ES (1) ES2142729B1 (en)
WO (1) WO1999006441A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES400418A1 (en) * 1972-03-03 1975-01-01 Chacon Mejias Procedure for the isolation and obtaining of proteins constituting a preventive and curative vaccine of malignant tumor processes. (Machine-translation by Google Translate, not legally binding)
ES410892A1 (en) * 1973-01-23 1975-12-01 Chacon Mejias Process for the production of an injectable preparation
JPS60190720A (en) * 1984-03-09 1985-09-28 Agency Of Ind Science & Technol Antitumor agent having acyl group
EP0691848A1 (en) * 1993-04-07 1996-01-17 Eisai Co., Ltd. Immunopotentiative and infection-protective agent, containing two or more bacillus, egg white and garlic
WO1995004539A1 (en) * 1993-08-11 1995-02-16 Ahc Inc. Immunopotentiator and method of immunopotentiating animal with the same

Also Published As

Publication number Publication date
WO1999006441A1 (en) 1999-02-11
ES2142729A1 (en) 2000-04-16
AU8442498A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
ATE183514T1 (en) HUMAN PROTEIN P53 PEPTIDES FOR USE IN HUMAN CYTOTOXIC T CELL RESPONSE-INDUCING COMPOSITIONS AND HUMAN P53 PROTEIN SPECIFIC T LYMPHOCYTES
BRPI9605663B8 (en) Bis(resorcinyl) triazines.
EA199901031A1 (en) Derivatives of benzimidazole
GB9720054D0 (en) Biological products
LV12493A (en) Pharmaceutical compositions containing plasma protein
AU7126281A (en) N-(vinblastinoyl-23)derivatives of amino acid and peptides
BR9809445A (en) Polypeptide comprising an immunogenic portion of a m antigen. tubercolosis, dna molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, processes for inducing protective immunity in a patient, tuberculosis detection process in a patient, and, diagnostic kit.
AR006188A1 (en) "PHARMACEUTICAL COMPOSITION TO INHIBIT SERINPROTEASE ACTIVITY, IN VITRO METHOD TO INHIBIT SERINPROTEASE ACTIVITY AND METHOD TO PREPARE SUCH COMPOSITION".
AR017866A1 (en) METHOD TO INCREASE THE IMMUNORESPUESTAS OF VACCINES OF NUCLEIC ACIDS, PHARMACEUTICAL COMPOSITIONS OF APPLICATION IN SUCH METHOD, PROCEDURE TO PREPARE SUCH COMPOSITIONS AND VACCINES USED IN SUCH METHOD.
BR0015137A (en) Neisserial antigenic peptides
FI964681A (en) Lactobacillus strains of human origin, preparations containing them and their uses
ATE232109T1 (en) SYNTHETIC MULTIPLE TANDEM REPEATS OF MUCIN PEPTIDE AND ITS DERIVATIVES AND THEIR USE
DE69906128D1 (en) REACTION PRODUCTS OF HYALURONIC ACID AND NATURAL AMINO ACIDS AND THEIR USE IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS
CA2413156A1 (en) Expression vectors
DE68916932D1 (en) ANTIMICROBIAL PEPTIDES, COMPOSITIONS CONTAINING THEM AND USES THEREOF.
NZ332233A (en) Denaturants for sympathomimetic amine salts to make these compounds less suitable as starting materials for the production of illegal drugs
ATE211391T1 (en) USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH CYTOTOXIC ACTION
AR002742A1 (en) ADIPOSE TYPE REGULATORY PROTEIN, PROCEDURE TO PRODUCE SUCH PROTEIN, PHARMACEUTICAL FORMULATIONS INCLUDING IT, ISOLATED DNA MOLECULES THAT CODES SUCH PROTEIN, VECTOR AND RECOMBINANT CELLS THAT INCLUDE SUCH DNA
ATE314474T1 (en) CLONING OF THE GENE FOR THE T GONDII PROTEIN GP 28.5 PEPTIDE FRAGMENTS FROM THIS PROTEIN AND THEIR USES.
ES2142729B1 (en) PROTEIN PRODUCT, PROCEDURE FOR ITS PREPARATION, COMPOSITIONS THAT CONTAIN IT, AND ITS USE IN MEDICINES.
CS55990A3 (en) Phenylhydrazones, process of their preparation and cosmetic preparations and pharmaceuticals made therefrom
AR031753A1 (en) PROTEIN PRODUCT, PROCEDURE FOR PREPARATION, COMPOSITIONS CONTAINING IT, AND USE IN MEDICATIONS
BR9303903A (en) Modified or cleaved platelet factor-4 and process for its preparation, pharmaceutical formulation, compound and vector of recombinant DNA and host cell
BR9507473A (en) DNA sequence isolated vector host cell process to produce a homogeneous gp350 protein homogeneous gp350 protein pharmaceutical composition and use in homogeneous gp350 protein
NZ335136A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000416

Kind code of ref document: A1

Effective date: 20000416

PC2A Transfer of patent
PC2A Transfer of patent

Effective date: 20130327

FD2A Announcement of lapse in spain

Effective date: 20171106